Abstract:E3 ubiquitin ligases engage their substrates via ‘degrons’ - short linear motifs typically located within intrinsically disordered regions of substrates. As these enzymes are large, multi-subunit complexes that generally lack natural small-molecule ligands and are hard to drug via conventional means, alternative strategies are needed to target them in diseases, and peptide-based inhibitors derived from degrons represent a promising approach. Here we explore peptide inhibitors of Cdc20, a substrate-recognition subunit and activator of the E3 ubiquitin ligase the anaphase promoting complex/cyclosome (APC/C) that is essential in mitosis and consequently of interest as an anti-cancer target. APC/C engages substrates via degrons that include the ‘Destruction box’ (D-box) motif. We used a rational design approach to construct binders containing unnatural amino acids aimed at better filling a hydrophobic pocket on the surface of Cdc20. We confirmed binding by thermal-shift assays and surface plasmon resonance and determined the structures of a number of the Cdc20-peptide complexes. Using a cellular thermal shift assay we confirmed that the D-box peptides also bind to and stabilise Cdc20 in the cell. We found that the D-box peptides inhibit ubiquitination activity of APC/C and are more potent than the small molecule inhibitor Apcin. Lastly, these peptides function as portable degrons capable of driving the degradation of a fused fluorescent protein. Interestingly, we find that although inhibitory activity of the peptides correlates with Cdc20-binding affinity, degradation efficacy does not, which may be due to the complex nature of APC/C regulation and effects of degron binding of subunit recruitment and conformational changes. Our study lays the groundwork for the further development of these peptides as molecular therapeutics for blocking APC/C as well as potentially also for harnessing APC/C for targeted protein degradation.

High-Affinity Peptidomimetic Inhibitors of the DCN1-UBC12 Protein-Protein Interaction.

A Potent Small-Molecule Inhibitor of the DCN1-UBC12 Interaction That Selectively Blocks Cullin 3 Neddylation

Targeting DCN1-UBC12 Protein-Protein Interaction for Regulation of Neddylation Pathway

Targeting Cullin-RING Ubiquitin Ligases and the Applications in PROTACs

Selective inhibition of cullin 3 neddylation through covalent targeting DCN1 protects mice from acetaminophen-induced liver toxicity

Development of phenyltriazole thiol-based derivatives as highly potent inhibitors of DCN1-UBC12 interaction

Inhibition of Autophagy by a Small Molecule Through Covalent Modification of the LC3 Protein

Modulation of Cullin-RING E3 ubiquitin ligase-dependent ubiquitination by small molecule compounds

Discovery of Potent and Selective 2-(Benzylthio)pyrimidine-based DCN1-UBC12 Inhibitors for Anticardiac Fibrotic Effects

Structural Basis for the Function of DCN-1 in Protein Neddylation

Targeting Cullin-RING E3 ligases for anti-cancer therapy:efforts on drug discovery

CAND1 inhibits Cullin-2-RING ubiquitin ligases for enhanced substrate specificity

Development of D-box peptides to inhibit the Anaphase Promoting Complex/Cyclosome

A Potent and Selective Inhibitor for the UBLCP1 Proteasome Phosphatase.

Basis for metabolite-dependent Cullin-RING ligase deneddylation by the COP9 signalosome

Optimization of Peptidomimetics as Selective Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction.

The co-crystal structure of Cbl-b and a small-molecule inhibitor reveals the mechanism of Cbl-b inhibition

Targeting Neddylation Pathways to Inactivate Cullin-RING Ligases for Anticancer Therapy

Phage display to identify Nedd8-mimicking peptides as inhibitors of the Nedd8 transfer cascade.

Anticancer Drug Discovery by Targeting Cullin Neddylation

Cullin-RING Ligases as attractive anti-cancer targets.